You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Programmed Cell Death Receptor Ligand 1 (PD-L1)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)

Active, not recruiting
  • Metastatic Nonsmall Cell Lung Cancer
  • Non Small Cell Lung Cancer
  • Stereotactic Body Radiotherapy
  • Philadelphia, Pennsylvania
    Philadelphia CyberKnife
Mar 15, 2022

NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Capsulized Fecal Microbiota Transplant
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 12, 2021

Molecular Subtyping of Extensive Stage Small Cell Lung Cancer

Recruiting
  • SCLC,Extensive Stage
  • PD-(L)1 antibody immunotherapy
  • Beijing, Beijing, China
    Peking University Cancer Hospital & Institute
Jul 3, 2023

Advanced NSCLC Trial (BNT116, Cemiplimab)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jan 3, 2023

Cancer Trial in United States (JTX-4014)

Active, not recruiting
  • Cancer
  • Denver, Colorado
  • +3 more
Sep 9, 2022

Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and

Recruiting
  • Head and Neck Cancer
  • Strasbourg, France
    Institut de cancérologie Strasbourg Europe
Apr 14, 2022

NSCLC Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +2 more
  • Hefei, Anhui, China
  • +16 more
Oct 14, 2022

Advanced Melanoma Trial in Worldwide (lenvatinib, pembrolizumab)

Active, not recruiting
  • Advanced Melanoma
  • Chandler, Arizona
  • +22 more
Jul 21, 2022

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

NSCLC Trial (biological, drug, radiation)

Withdrawn
  • Non-small Cell Lung Cancer
  • avelumab
  • +21 more
  • (no location specified)
Mar 17, 2021

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Toripalimab (anti-programmed death-1 inhibitor)
  • +4 more
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Oct 24, 2023

Head and Neck Squamous Cell Carcinoma Trial (biological, drug, radiation)

Withdrawn
  • Head and Neck Squamous Cell Carcinoma
  • Avelumab
  • +21 more
  • (no location specified)
Mar 17, 2021

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Programmed Cell Death 1 Trial in Assiut (Thoracic Paravertebral block)

Recruiting
  • Programmed Cell Death 1
  • Thoracic Paravertebral block
  • Assiut, Egypt
    South Egypt Cancer Institute
Dec 5, 2020

Urothelial Carcinoma Trial (biological, drug, radiation)

Withdrawn
  • Urothelial Carcinoma
  • avelumab
  • +19 more
  • (no location specified)
Mar 17, 2021

Malignant Pleural Mesothelioma Trial in Edegem, Ghent, Sint-Niklaas (Dendritic cell vaccination, Atezolizumab,

Not yet recruiting
  • Malignant Pleural Mesothelioma
  • Dendritic cell vaccination
  • +2 more
  • Edegem, Antwerp, Belgium
  • +2 more
Feb 28, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer Recurrent
  • Toripalimab, Anlotinib and Chemotherapy
  • (no location specified)
Apr 24, 2023

Lung Cancer, Non-Small Cell Trial in Worldwide (Pembrolizumab, Dostarlimab, GSK4428859A)

Recruiting
  • Lung Cancer, Non-Small Cell
  • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • +14 more
Dec 26, 2022